Tae-You Kim

List of Publications by Year
in descending order

135 papers	11,204 citations	109264 35 h-index	31818 101 g-index
136 all docs	136 docs citations	136 times ranked	15534 citing authors

#	Article	IF	Citations
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	6.3	3,224
2	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1224-1235.	5.1	1,932
3	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	3.4	746
4	Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncology, The, 2014, 15, 767-774.	5.1	713
5	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637.	2.9	472
6	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nature Genetics, 2020, 52, 594-603.	9.4	380
7	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	5.1	336
8	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
9	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PLoS ONE, 2015, 10, e0139749.	1.1	183
10	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Research, 2015, 17, 33.	2.2	138
11	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. Journal of Clinical Oncology, 2017, 35, 4073-4073.	0.8	133
12	STAT3 inhibits the degradation of HIF-1Î± by pVHL-mediated ubiquitination. Experimental and Molecular Medicine, 2008, 40, 479.	3.2	103
13	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 3111-3123.	0.8	100
14	Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World Journal of Gastroenterology, 2015, 21, 1457.	1.4	98
15	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Clinical Cancer Research, 2019, 25, 6141-6147.	3.2	98
16	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 2016, 7, 76604-76612.	0.8	93
17	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2015, 47, 607-615.	1.3	93
18	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer, 2015, 18, 824-832.	2.7	91

#	Article	IF	Citations
19	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	0.8	76
20	Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 3389-3395.	0.7	69
21	Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget, 2016, 7, 58007-58021.	0.8	63
22	Histone Deacetylase Inhibitors for Cancer Therapy. Epigenetics, 2006, 1, 15-24.	1.3	61
23	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. Clinical Cancer Research, 2015, 21, 2520-2529.	3.2	59
24	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Cancer Research and Treatment, 2016, 48, 171-179.	1.3	56
25	Prognostic implication of antitumor immunity measured by the neutrophilâ€“lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer, 2017, 20, 254-262.	2.7	51
26	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer, 2017, 123, 3513-3523.	2.0	50
27	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget, 2017, 8, 2329-2341.	0.8	50
28	Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 569-577.	3.7	50
29	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. International Journal of Cancer, 2013, 132, 2209-2216.	2.3	49
30	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2013, 45, 325-333.	1.3	49
31	Activation of WNT/Î²â€catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. International Journal of Cancer, 2019, 144, 389-401.	2.3	48
32	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Nonâ€“Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 238-243.	0.6	45
33	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. British Journal of Cancer, 2016, 115, 164-171.	2.9	43
34	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or <i>POLE</i>-Mutated Metastatic or Unresectable Colorectal Cancer. Cancer Research and Treatment, 2020, 52, 1135-1144.	1.3	43
35	Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. British Journal of Cancer, 2017, 116, 1012-1020.	2.9	40
36	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Research and Treatment, 2019, 51, 510-518.	1.3	39

#	Article	IF	Citations
37	Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumorâ€“Immune Microenvironment in Colorectal Cancers. Clinical Cancer Research, 2020, 26, 870-881.	3.2	37
38	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Investigational New Drugs, 2018, 36, 1072-1084.	1.2	32
39	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. British Journal of Cancer, 2019, 120, 797-805.	2.9	32
40	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clinical and Molecular Hepatology, 2020, 26, 328-339.	4.5	32
41	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer, 2016, 19, 597-606.	2.7	31
42	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. Journal of Clinical Oncology, 2016, 34, 4078-4078.	0.8	30
43	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 757-764.	3.3	27
44	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	3.2	27
45	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Oncologist, 2019, 24, 18-e24.	1.9	25
46	Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. World Journal of Gastroenterology, 2015, 21, 9749.	1.4	24
47	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 165-178.	4.2	23
48	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208.	2.9	22
49	Dynamic cohesinâ€mediated chromatin architecture controls epithelialâ€“mesenchymal plasticity in cancer. EMBO Reports, 2016, 17, 1343-1359.	2.0	21
50	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. Journal of Clinical Oncology, 2016, 34, 2508-2508.	0.8	21
51	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0145004.	1.1	20
52	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2016, 48, 28-36.	1.3	20
53	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer, 2015, 15, 721.	1.1	19
54	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. British Journal of Cancer, 2016, 115, 1201-1205.	2.9	19

#	Article	IF	Citations
55	Korean Cancer Patientsâ€™ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. Cancer Research and Treatment, 2017, 49, 1033-1043.	1.3	19
56	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. PLoS ONE, 2020, 15, e0232754.	1.1	19
57	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 226-226.	0.8	19
58	Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. Nucleic Acids Research, 2016, 44, 558-572.	6.5	18
59	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. Journal of Pain and Symptom Management, 2014, 48, 13-25.	0.6	17
60	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. Clinical Epigenetics, 2015, 7, 63.	1.8	17
61	Patientâ€derived organoids as a preclinical platform for precision medicine in colorectal cancer. Molecular Oncology, 2022, 16, 2396-2412.	2.1	17
62	Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. Experimental and Molecular Medicine, 2008, 40, 639.	3.2	15
63	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist, 2015, 20, 926-933.	1.9	15
64	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptorâ€“Positive Early Breast Cancer. Clinical Breast Cancer, 2020, 20, 98-107.e1.	1.1	15
65	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS ONE, 2016, 11, e0151406.	1.1	15
66	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. Cancer Research and Treatment, 2016, 48, 990-997.	1.3	15
67	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. Scientific Reports, 2021, 11, 16333.	1.6	14
68	More Accurate Prediction of Metastatic Pancreatic Cancer Patientsâ€™ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS ONE, 2016, 11, e0145692.	1.1	14
69	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. Gastric Cancer, 2017, 20, 164-174.	2.7	13
70	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. Journal of Breast Cancer, 2017, 20, 347.	0.8	13
71	TGF-Î² Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer Research and Treatment, 1970, 47, 101-109.	1.3	13
72	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 2019, 51, 223-239.	1.3	13

#	Article	IF	Citations
73	NFATC3â€“PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. Cancer Research and Treatment, 2019, 51, 391-401.	1.3	13
74	EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. Oncogene, 2022, 41, 2026-2038.	2.6	13
75	Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer. Experimental and Molecular Medicine, 2022, 54, 156-168.	3.2	13
76	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	1.5	12
77	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
78	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC Cancer, 2016, 16, 515.	1.1	11
79	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. Gastric Cancer, 2016, 19, 421-430.	2.7	11
80	Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. Nuclear Medicine and Molecular Imaging, 2017, 51, 147-153.	0.6	11
81	Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers. Diagnostics, 2021, 11, 51.	1.3	11
82	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Research and Treatment, 2015, 47, 790-795.	1.3	10
83	Src as a Therapeutic Target in Biliary Tract Cancer. Molecular Cancer Therapeutics, 2016, 15, 1515-1524.	1.9	10
84	Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. Molecular Oncology, 2018, 12, 1398-1409.	2.1	10
85	Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	10
86	Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. Scientific Reports, 2020, 10, 19467.	1.6	10
87	Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. Scientific Reports, 2021, 11, 14609.	1.6	10
88	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Cancer Research and Treatment, 2016, 48, 1045-1055.	1.3	10
89	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. BMC Cancer, 2015, 15, 690.	1.1	9
90	Perceived needs for the information communication technology (ICT)â€based personalized health management program, and its association with information provision, healthâ€related quality of life (HRQOL), and decisional conflict in cancer patients. Psycho-Oncology, 2017, 26, 1810-1817.	1.0	9

#	Article	IF	Citations
91	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Research and Treatment, 2021, 53, 1096-1103.	1.3	9
92	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 707-714.	1.2	8
93	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. BMC Cancer, 2018, 18, 252.	1.1	7
94	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.. Journal of Clinical Oncology, 2014, 32, 4058-4058.	0.8	7
95	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 339-339.	0.8	7
96	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 4596-4596.	0.8	7
97	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80.	0.5	7
98	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. Materials, 2015, 8, 519-534.	1.3	6
99	Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. American Journal of Pathology, 2015, 185, 666-678.	1.9	6
100	Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas. PLoS ONE, 2021, 16, e0246356.	1.1	6
101	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3076-3076.	0.8	6
102	Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 4121-4121.	0.8	6
103	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. American Journal of Cancer Research, 2015, 5, 3376-88.	1.4	6
104	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767.	1.9	5
105	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. Cancer Research and Treatment, 2019, 51, 1527-1539.	1.3	5
106	Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis. Cancer Research and Treatment, 2022, 54, 383-395.	1.3	4
107	First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS2597-TPS2597.	0.8	4
108	KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS3631-TPS3631.	0.8	4

#	Article	IF	Citations
109	Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.. Journal of Clinical Oncology, 2017, 35, 252-252.	0.8	4
110	Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells. Biochemical and Biophysical Research Communications, 2021, 558, 209-215.	1.0	3
111	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, 4078-4078.	0.8	3
112	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. Journal of Clinical Oncology, 2013, 31, 4044-4044.	0.8	3
113	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. BMC Cancer, 2019, 19, 421.	1.1	2
114	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2012, 30, 269-269.	0.8	2
115	Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion. Diseases of the Colon and Rectum, 2022, Publish Ahead of Print, .	0.7	2
116	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2021, 39, 1335-1347.	1.2	1
117	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptorâ€“Positive Metastatic Breast Cancer in Korea. Cancer Research and Treatment, 2017, 49, 454-463.	1.3	1
118	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, 416-416.	0.8	1
119	Longitudinal monitoring of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 189-189.	0.8	1
120	Role of Dedicated Subspecialized Radiologists in Multidisciplinary Team Discussions on Lower Gastrointestinal Tract Cancers. Korean Journal of Radiology, 2022, 23, .	1.5	1
121	Fabrication of biodegradable polymeric micro chambers encapsulated with pulverized drug for bacteria-based microrobots. , 2014, , .		0
122	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. Nutrition and Cancer, 2016, 68, 750-755.	0.9	0
123	Reply to â€˜Comment on â€˜Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification systemâ€. British Journal of Cancer, 2018, 118, e4-e4.	2.9	0
124	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. The Korean Journal of Hematology, 2005, 40, 192.	0.7	0
125	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. Journal of Clinical Oncology, 2012, 30, 623-623.	0.8	0
126	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3624-3624.	0.8	0

#	Article	IF	Citations
127	The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14580-e14580.	0.8	0
128	Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients.. Journal of Clinical Oncology, 2012, 30, e11532-e11532.	0.8	0
129	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. Journal of Clinical Oncology, 2013, 31, 182-182.	0.8	0
130	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. Journal of Clinical Oncology, 2013, 31, e15066-e15066.	0.8	0
131	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2014, 32, 1038-1038.	0.8	0
132	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. Journal of Clinical Oncology, 2016, 34, 4075-4075.	0.8	0
133	Korean Cancer Patientsâ€™ Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067.	0.8	0
134	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. Journal of Clinical Oncology, 2017, 35, 460-460.	0.8	0
135	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 454-454.	0.8	0